pharmacy scholarship: scott akers

o'neill mj, yoneda zt, crawford dm, ye f, ao m, pitchford lm, rathmacher ja, murray kt, akers ws, roden dm, michaud gf, shoemaker mb. 2-hydroxybenzylamine (2-hoba) to prevent early recurrence of atrial fibrillation after catheter ablation: protocol for a randomized controlled trial including detection of af using a wearable device. trials. 2021;22(1):576. doi:10.1186/s13063-021-05553-6

han sh, goins cm, arya t, shin wj, maw j, hooper a, sonawane dp, porter mr, bannister be, crouch rd, lindsey a a, lakatos g, martinez sr, alvarado j, akers ws, wang ns, jung ju, macdonald jd, stauffer sr. structure-based optimization of ml300-derived, noncovalent inhibitors targeting the severe acute respiratory syndrome coronavirus 3cl protease (sars-cov-2 3cl(pro)). j med chem. 2021;doi:10.1021/acs.jmedchem.1c00598

arnold dh, bowman n, reiss tf, hartert tv, akers ws, seger dl. adverse events associated with weight-based, high-dose montelukast exposures in children. clin toxicol. 2020;58(2):145-146. doi:10.1080/15563650.2019.1609686

mercer sl, wallace jl, akers ws, dalby r. bridging the gap: an integrated learning exercise in pulmonary formulations. am j pharm educ. 2020;84(6):ajpe8220. research and education posters presented at the 121st virtual annual meeting of the american association of colleges of pharmacy, july 13-31, 2020. doi:10.5688/ajpe8220

collier s, uroza sf, mccormac m, deweese je, akers ws. connecting antibody structure and function to pharmacy practice through a point-of-care testing lab. am j pharm educ. 2020;84(6):ajpe8220. research and education posters presented at the 121st virtual annual meeting of the american association of colleges of pharmacy, july 13-31, 2020. doi:10.5688/ajpe8220

arnold dh, van driest sl, reiss tf, king jc, akers ws. pilot study of peak plasma concentration after high-dose oral montelukast in children with acute asthma exacerbations. j clin pharmacol. 2020; doi:10.1002/jcph.1738

pitchford lm, driver pm, fuller jc jr, akers ws, abumrad nn, amarnath v, milne gl, chen sc, ye f, roberts lj ii, shoemaker mb, oates ja, rathmacher ja, boutaud o. safety, tolerability, and pharmacokinetics of repeated oral doses of 2-hydroxybenzylamine acetate in healthy volunteers: a double-blind, randomized, placebo-controlled clinical trial. bmc pharmacol toxicol. 2020;21(1):3. doi:10.1186/s40360-020-0382-y

akers ws. clinical research study in ventricular tachycardia ablation – pharmacokinetics and pharmacodynamics of ryanodex. paper presented at: american heart association; may 2019; dallas, tx.

pitchford lm, rathmacher ja, fuller jc, jr., daniels js, morrison, rd, akers ws, abumrad nn, amarnath v, currey pm, roberts lj, oates ja, boutaud o. first-in-human study assessing safety, tolerability, and pharmacokinetics of 2-hydroxybenzylamine acetate, a selective dicarbonyl electrophile scavenger, in healthy volunteers. bmc pharmacol toxicol. 2019;20(1):1. doi: 10.1186/s40360-018-0281-7

akers ws. pharmacokinetics for the pharmaceutical scientist – short course. paper presented at: drug metabolism and pharmacokinetics division, seventh wave laboratories llc; july 2019; maryland heights, mo.

akers ws. pharmacokinetics for the pharmaceutical scientist – short course. paper presented at: pharmacology and toxicology division, seventh wave laboratories llc; november 2019; maryland heights, mo.

akers ws, barnett j. building research collaborations across institutions. paper presented at: inspire 2018 the aacp interim meeting; february 24-27, 2018; long beach, ca.

akers ws. a novel molecular target in atrial fibrillation – pharmacokinetics and pharmacodynamics of 2-hoba. paper presented at: american heart association; may 2018; chicago, il.

oestreich jh, steinhubl sr, ferraris sp, loftin cd, akers ws. effect of genetic variation in p2y12 on trap-stimulated platelet response in healthy subjects. j thromb thrombolysis. 2014;38(3):372-379. doi: 10.1007/s11239-014-1058-5

akers ws. establishing a research scholars program and cross institutional partnerships. poster presented at: american association of colleges of pharmacy annual meeting; july 2014; grapevine, tx.

akers ws, ingram k, fowler mw, vergne mj, knollman bc, segar dl, dawling sp. an in-vitro model of intralipid emulsion treatment for verapamil toxicity. am j pharm educ. 2014;78(5):1. meeting abstracts presented at the 115th annual meeting of the american associaton of colleges of pharmacy, july 26-30, 2014. doi:10.5688/ajpe785111

cox zl, calcutt mw, morrison tb, akers ws, davis mb, lenihan dj. elevation of plasma milrinone concentrations in stage d heart failure associated with renal dysfunction. j cardiovasc pharmacol ther. 2013;18(5):433-438. doi: 10.1177/1074248413489773

oestreich jh, ferraris sp, steinhubl sr, akers ws. pharmacodynamic interplay of the p2y(1), p2y(12), and txa(2) pathways in platelets: the potential of triple antiplatelet therapy with p2y(1) receptor antagonism. thromb res. 2013;131(2):e64-70. doi: 10.1016/j.thromres.2012.11.019

akers ws, deweese je, fowler mw, mercer sl. back to the basics: integrating curricular content in the pharmaceutical sciences through laboratory based exercises. poster presented at: american association of colleges of pharmacy annual meeting; july 14-18, 2012; kissimmee, fl.

akers ws. career growth areas in pharmacology: colleges of pharmacy. paper presented at: national directors of graduate studies in pharmacology and physiology annual meeting; july 2011; east lansing, mi.

steil cf, akers ps, chirico mj, thompson jr. development and implementation of a collaborative interprofessional learning program. am j pharm educ. 2011;75(5):105. doi: 10.5688/ajpe755105

fowler mw, deweese je, dilks hh, mercer sl, phipps sd, mccormack j, akers ws. development of an integrated biomedical and pharmaceutical sciences teaching laboratory. am j pharm educ. 2011;75(5). doi: 10.5688/ajpe755105

oestreich jh, steinhubl sr, ferraris sp, akers ws. high residual platelet reactivity on standard clopidogrel maintenance dose predicts increased responsiveness to the double-standard dose in an assay-dependent manner. thromb haemost. 2011;105(5):927-930. doi: 10.1160/th10-09-0603

fowler mw, deweese je, dilks hh, mercer sl, phipps sd, mccormack j, akers ws. an integrated biomedical and pharmaceutical sciences teaching laboratory for first-year pharmd students. am j pharm educ. 2011;75(5):3. doi: 10.5688/ajpe755105

akers ws, mercer sl. an integrated laboratory approach to drug dissolution: focus on drug formulation and release. am j pharm educ. 2011;75(5). doi: 10.5688/ajpe755105

akers ws, mercer sl. use of a high throughput assay to emphasize key concepts in drug metabolism and drug interactions. am j pharm educ. 2011;75(5). doi: 10.5688/ajpe755105

akers ws, oh jj, oestreich jh, ferraris s, wethington m, steinhubl sr. pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral p2y12 receptor antagonist. j clin pharmacol. 2010;50(1):27-35. doi: 10.1177/0091270009344986

oestreich jh, holt j, dunn sp, smyth ss, campbell cl, charnigo r, akers ws, steinhubl sr. considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel. coron artery dis. 2009;20(3):207-213. doi: 10.1097/mca.0b013e328329924b

oestreich jh, ferraris s, akers ws. significant pharmacodynamic variability of p2y12 receptor mediated platelet response in healthy volunteers as assessed by comprehensive platelet function analysis. arterioscler thromb vasc biol. 2009;29(7):121. doi: doi:10.1161/atv.0b013e3181ab66e7

oestreich jh, ferraris s, akers ws. evaluating the genetic influence of p2y12 and gp iib/iiia receptor polymorphisms on platelet response in healthy volunteers. j am pharm assoc. 2008;48(2):270. doi: 10.1331/japha.2008.08512

oestreich jh, ferraris s, akers ws. pharmacodynamic variability of p2y12 receptor mediated platelet response in healthy volunteers. poster presented at: midwest platelet conference; october 2008; lexington, ky.

steinhubl sr, oh jj, oestreich jh, ferraris s, charnigo r, akers ws. transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. thromb res. 2008;121(4):527-534. doi: 10.1016/j.thromres.2007.05.020

holt j, akers ws, oestreich jh, steinhubl sr. effect of increased maintenance dose of clopidogrel on platelet aggregation. poster presented at: american college of cardiology annual scientific sessions; march 2007; new orleans, la.

boustany-kari cm, gong m, akers ws, guo z, cassis la. enhanced vascular contractility and diminished coronary artery flow in rats made hypertensive from diet-induced obesity. int j obes. 2007;31(11):1652-1659. doi: 10.1038/sj.ijo.0803426

akers ws. overview of platelet assays: applications for interpreting clinical trial data. paper presented at: sanofi-aventis pharmaceuticals, regional cardiovascular medical training meeting; february 2007; jackson hole, wy.